Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy

To the Editor:

Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe delayed complication after pulmonary embolism. Known risk factors of CTEPH include acute pulmonary embolism, the degree of pulmonary arterial occlusion, pulmonary embolism recurrence, splenectomy, ventriculo-arterial shunts, infected pacemakers and blood group O [1, 2]. Symptomatic pulmonary embolism is found in almost three-quarters of patients with CTEPH [3]. Cyproterone acetate, a synthetic steroidal antiandrogen drug with additional progestogen and antigonadotropic properties, is a major risk factor of venous thromboembolic disease [4, 5]. We report the first case of severe CTEPH occurring in the context of cyproterone acetate long-term exposure.

A 55-year-old female was referred to our centre (French referral centre for pulmonary hypertension) for pulmonary hypertension. She was a former smoker (30 pack-years) and her medical history included migraine, systemic hypertension and severe acne (treated with cyproterone acetate, 50 mg daily) between 1992 and 2010 associated with ethinylestradiol therapy. The patient had no past history of pulmonary embolism or deep vein thrombosis. No risk factors for CTEPH other than cyproterone acetate exposure were identified. In 2010, the patient reported exertional dyspnoea and cyproterone acetate was stopped. The patient experienced progressive dyspnoea during the following 18 months, and the patient was in New York Heart Association (NYHA) functional class III at the time of the first evaluation. Pulmonary hypertension was suspected on Doppler echocardiography and right heart catheterisation confirmed severe pre-capillary pulmonary hypertension with a mean pulmonary arterial pressure of 52 mmHg, a normal pulmonary artery wedge pressure, a low cardiac index of 1.76 L·min⁻¹·m^-2, an increased total pulmonary resistance of 19.6 Wood Units (WU), and a low mixed venous oxygen saturation of 51%. Her 6-min walk distance was 265 m. A ventilation/perfusion lung scan showed multiple bilateral perfusion defects with normal ventilation. Helical computed tomography of the chest and pulmonary angiogram (fig. 1a and b) confirmed the diagnosis of CTEPH with bilateral proximal obstruction of the pulmonary arteries. Pulmonary endarterectomy was successfully performed allowing removal of organised material (fig. 1c). Evolution was favourable with a decrease of total pulmonary resistance to 6 WU immediately after surgery. 2 years after surgery the patient showed persistent clinical benefit (NYHA functional class I).

• Download figure
• Open in new tab
• Download powerpoint

Figure 1.

a) Selective pulmonary angiogram of the right and left main pulmonary arteries confirmed the diagnosis of chronic thromboembolic pulmonary hypertension with bilateral proximal obstruction of the pulmonary arteries. b) Computed tomography of the chest showing organised thromboembolic material in the main right pulmonary artery (arrow). c) Organised thromboembolic material removed during pulmonary endarterectomy.

We report the first case of CTEPH potentially associated with long-term exposure to cyproterone acetate. This antiandrogen therapy, widely used in the field of oncology for the treatment of prostatic neoplasia (100–300 mg·day⁻¹), is a major risk factor of pulmonary embolism in males with prostatic neoplasia [6]. Lower doses of cyproterone acetate (2–100 mg·day⁻¹) are commonly used outside the oncological setting, and cyproterone acetate has been proposed for the management of severe acne and hirsutism, reduction of sexual pulsion and as a method of birth control, in addition to ethinylestradiol [7]. Even at these lower doses (2 mg·day⁻¹), cyproterone acetate is still associated with high risks of venous thromboembolic disease (seven-fold increased risk) [4, 7]. It is worth noting that, this risk increases with the duration of exposure and with the patient’s age [4]. Due to this, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (EMEA) recently reviewed the risk/benefit ratio of this drug, particularly the association of cyproterone acetate (2 mg)/ethinylestradiol (35 μg), which is widely used across Europe for the treatment of acne or as oral contraception. The EMEA maintained that these drugs could be used in the treatment of moderate-to-severe acne related to androgen sensitivity and/or hirsutism in females of reproductive age, but only after topical therapy or systemic antibiotic treatments failed [8]. Due to the fact that these drugs act as hormonal contraceptives, they cannot be used in combination with other hormonal contraceptives [8]. Notably, hormonal therapy is not recognised as a usual risk factor for CTEPH [2, 3, 9]. However, the present case indicates that long-term exposure to a high dose of cyproterone acetate may be a risk factor for CTEPH. As previously emphasised in pulmonary arterial hypertension [10–12], complete information on drug exposure should be systematic in patients presenting with CTEPH in order to identify as yet unrecognised possible drug-induced cases. Several drugs have been recognised recently as being associated with an increased risk of pulmonary arterial hypertension, e.g. dasatinib in patients with chronic myelogenous leukaemia. Beside its role in thrombosis, cyproterone acetate should also be recognised as an increased risk factor of CTEPH. Thus, clinicians should also consider chronic venous thromboembolism as CTEPH in patients exposed to cyproterone acetate.

• Received August 28, 2013.
• Accepted September 18, 2013.

• ©ERS 2014